A Multicenter Randomized Double-Blind Placebo-Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Ulcerative Colitis Who Responded to Induction Treatment in M16-067 or M16-065

The study will enroll subjects who have completed Study M16-067 or Study M16-065 and have achieved clinical response, defined as decrease from Baseline of induction study of Adapted Mayo score greater than or equal to 2 points and greater than or equal to 30%, PLUS a decrease in rectal bleeding sub-score (RBS) greater than or equal to 1 or an absolute RBS less than or equal to 1 .

You may be eligible for this study if you meet the following criteria:

• Conditions:
  ulcerative colitis
• Age: - 99 Years
• Gender: All